CME

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

This CME activity from ASCO 2012 reviews crizotinib in patients with ALK-positive non-small cell lung cancer.

Carfilzomib, Lenalidomide, Low-Dose Dexamethasone Provides Rapid, Deep Responses in Patients with Newly Diagnosed Multiple Myeloma

Carfilzomib, Lenalidomide, Low-Dose Dexamethasone Provides Rapid, Deep Responses in Patients with Newly Diagnosed Multiple Myeloma

This CME activity from ASCO 2012 reviews carfilzomib, lenalidomide, and low-dose dexamethasone in patients with newly diagnosed multiple myeloma.

Pomalidomide Active in Patients with Multiple Myeloma Refractory to Lenalidomide, Bortezomib—or Both—and in Transplant Failures

Pomalidomide Active in Patients with Multiple Myeloma Refractory to Lenalidomide, Bortezomib—or Both—and in Transplant Failures

This CME activity reviews pomalidomide in combination with low-dose dexamethasone in patients with multiple myeloma refractory to lenalidomide, bortezomib, or both.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs